Medicine
Cartia XT 300 mg extended-release capsule
Cartia XT 300 mg extended-release capsule is a prescription medicine containing Diltiazem for oral use, marketed by Actavis Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Diltiazem
- Brand
- Cartia XT
- Strength
- 300 mg
- Dosage form
- Extended-release capsule
- Route
- Oral
- Packs
- 500 capsules, 90 capsules
- Marketing authorisation holder
- Actavis Pharma
- Manufacturers
- Actavis PharmaDirectRx
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C05AE03 Diltiazem
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 9 July 1998
- Identifiers
- RxCUI 830801, 830837, 830845 +5DailyMed set ID 2dc2b889-8443-4f7f-83be-86c68e179804, dbfda3a5-5602-6e47-e053-2995a90ac07bNDC 62037-600, 72189-344Application ANDA074752
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 500 capsule, extended release in 1 bottle | 62037-600-05 | Actavis Pharma | 23 June 1999 |
| 90 capsule, extended release in 1 bottle | 62037-600-90 | Actavis Pharma | 23 June 1999 |
| 90 capsule, extended release in 1 bottle | 72189-344-90 | DirectRx | 6 April 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 November 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Diltiazem 300 mg extended-release capsule.
- Diltiazem 300 mg extended-release capsuleAvailable on request—US FDA40 packs
- Tiadylt ER 300 mg extended-release capsuleAvailable on requestZydus LifesciencesIndiaUS FDA10 packs
- Cardizem CD 300 mg extended-release capsuleAvailable on requestBausch HealthUS FDA2 packs
- Tiazac Extended Release 300 mg extended-release capsuleAvailable on requestBausch HealthUS FDA2 packs
Other strengths and forms of Diltiazem
Clinical summary
Diltiazem is a calcium channel blocker indicated for the management of chronic stable angina and angina due to coronary artery spasm. It is available as extended-release capsules, tablets and extended-release tablets for oral and intravenous use. MedsAcross supplies Diltiazem for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DiltiazemFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cardizem prescribing information (Bausch Health) · U.S. National Library of Medicine, DailyMed
Need Cartia XT 300 mg extended-release capsule for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.